

Index

A

- Abscopal effect, 160–161
- Antiangiogenic therapy
 - BBB-stabilizing effect, 91
 - bevacizumab, 89–90
 - ligand binding prevention, 89
 - phase I and II trials, 90–91
 - prophylaxis of brain metastasis formation, 92–93
- Astrocytes, 45–46
- $\alpha_v\beta_3$ integrin, 27

B

- Blood-brain barrier (BBB)
 - animal models, 16
 - antiangiogenic therapy, 91
 - astrocytes, 46
 - in brain microenvironment, 51
 - chemotherapy, 137–138
 - efflux transporters and enzymatic proteins, 56
 - glucose and amino acids, 56
 - pericytes, 46
 - permeability and drug uptake, 64–65
 - radiation therapy, 161–162
 - structural feature, 55–56
- Blood-tumor barrier (BTB)
 - functional changes, 57–58
 - permeability and drug uptake, 64–65
 - structural changes
 - new blood vessel growth, 59
 - non-permeable and permeable lesions, 60–61
 - permeability variances, 62
 - VEGF, 60
 - ZO-1, 58–59
- Bradykinin, 51
- Brain metastasis
 - animal models
 - 231-BR mouse model vs. human samples, 17–18
 - hematogenous model, 16–17
 - implantation model, 16
 - spontaneous model, 17
 - antiangiogenic therapy
 - BBB-stabilizing effect, 91
 - bevacizumab, 89–90
 - ligand binding prevention, 89
 - phase I and II trials, 90–91
 - prophylaxis, 92–93
- BRAF, 97–98
- brain radiation, 10
- breast cancer
 - nomograms, 8
 - risk factors, 6–7
 - types, 6
- cytotoxic T lymphocyte antigen 4
 - immunomodulators, 98
- diagnosis and prognosis, 9–10
- EGFR in non-small cell lung cancer
 - dose escalation strategies, 97
 - gefitinib and erlotinib, 95, 97
 - phase II trials, 95–96
- glial fibrillary acid protein intermediate filaments, 19–20
- HER2 in breast cancer
 - afatinib, 95

- Brain metastasis (*cont.*)
- lapatinib, 94–95
 - MDA-MB-231, 93
 - trastuzumab, 94
 - immunostaining, 19–20
 - intraparenchymal and leptomeningeal metastases, 20–21
 - intravital microscopy, 80–81
 - lung cancer
 - GPA, 5–6
 - multivariate Cox regression analysis, 5
 - small and non-small cell, 4
 - melanoma, 8
 - metastatic niche, 21
 - microglia, 19–20
 - molecular pathways
 - COX-2 and ST6GALNAC5, 32–33
 - genes functionality, 22–24
 - genomic analysis, 21
 - heparanase, 34–35
 - HER2, 22, 25
 - PEDF, 33–34
 - TGF β , 35–36
 - transcription factors, 28–32
 - $\alpha_3\beta_1$ integrin, 27
 - VEGF, 25–27
 - molecular therapies, 8–9
 - MRI
 - blood pool agents, 73
 - blooming artifact, 74
 - breast cancer cells, 74–75
 - cell tracking, 74
 - differential ADC and dynamic contrast-enhancement characteristics, 71, 73
 - diffusion weighted imaging, 74
 - image contrasts, 70–71
 - superparamagnetic iron oxide nanoparticles, 72
 - volume measurements, enhancing vs. nonenhancing metastasis, 71–72
 - MRS, 75–76
 - multimodality imaging, 82–83
 - parallel and linear progression models, 19
 - PET
 - hypoxia, 77–78
 - natural biological molecules, 76
 - proliferation rate and DNA replication, 77
 - upregulated cell surface receptors, 78
 - predictive marker, 99–100
 - QOL (*see* Quality of life (QOL))
 - SPECT, 78
 - stereotactic radiosurgery, 10
 - surgery
 - adjuncts, 121–125
 - complications, 126
 - history, 110–111
 - methods, 119–121
 - mortality, 126
 - number of lesions, 116–117
 - post-operative management, 126
 - recurrent metastases, 118
 - role of, 111–113
 - survival, 126
 - treatment, 113–116
 - tumor size, 119
 - WBRT role, 125–126
 - surveillance epidemiology and end results registry, 3
 - symptomatic vs. asymptomatic disease, 4
 - treatment
 - chemokine receptor and ligand, 135
 - chemotherapy (*see* chemotherapy)
 - colonization, 134
 - medical treatment, 135–136
 - WBRT with temozolomide, 145
 - tumor sites, 18
 - vascular permeability
 - BBB, 55–57
 - BTB, 57–60
 - drug accumulation and effect, 63
 - kinetic analysis and drug uptake, 64–65
 - whole-body optical imaging
 - bioluminescence imaging, 79–80
 - fluorescent imaging, 79
 - sensitivity and high throughput, 78
 - stress effect, 80
 - tyrosine kinase inhibitor, 79
 - WNT pathway, 98–99
 - Brain microenvironment
 - cancer stem cells, 47
 - cell types
 - astrocytes, 45–46
 - microglia, 45
 - neurons, 44
 - oligodendrocytes, 46
 - pericytes, 46
 - metastatic tumor cell interactions
 - with astrocyte, 50–51
 - with microglia, 48–49
 - with neuron, 47–48
 - soluble factors, 51
 - Breast cancer
 - animal model, 16–17, 20
 - astrocytes, 46

- chemotherapy (*see* Chemotherapy)
 - heparanase, 35
 - HER2, 7, 93–95
 - integrins, 27
 - interactions between cell types, 47, 49–50
 - leptomeningeal carcinomatosis, 197
 - MRI, 71, 74–76
 - PEDF, 33–34, 51
 - transcription factors, 28
 - types, 6
 - Wnt/TCF signaling, 30
- C**
- Cancer stem cells, 47
 - Central nervous system (CNS) metastasis. *See* Brain metastasis
 - Chemotherapy
 - BBB, 137–138
 - carmustine wafer implants, 140
 - EGFR inhibitors, 140
 - issues, 136–137
 - multi-agent, 143
 - outcome measures, 137
 - parenchymal brain drug delivery, 137–138
 - pre-radiation, 144
 - single agent (*see* Single agent chemotherapy)
 - temozolomide, 139
 - topotecan, 139
 - Computed tomography (CT), 82, 115, 121, 123, 162, 190
 - Craniotomy, 112, 118, 121, 123, 125
 - Cyclooxygenase-2 (COX-2), 32–33
 - Cytotoxic T lymphocyte antigen 4 immunomodulators, 98
- D**
- Dormancy, 92–93
- E**
- Epidermal growth factor receptor (EGFR)
 - chemotherapy, 140
 - in non-small cell lung cancer
 - dose escalation strategies, 97
 - gefitinib and erlotinib, 95, 97
 - phase II trials, 95–96
 - Extracellular matrix (ECM), 27, 34, 35, 138
- G**
- Graded prognostic assessment (GPA)
 - lung cancer, 5–6
 - melanoma, 8
 - patient selection for surgical treatment, 114
- H**
- Hematologic malignancies, 4, 34
 - Heparanase, 34–35
 - Human epidermal growth factor receptor (HER2)
 - in breast cancer
 - afatinib, 95
 - lapatinib, 94–95
 - MDA-MB-231, 93
 - trastuzumab, 94
 - molecular pathways, 22, 25
- I**
- Immunomodulator, 160–161
 - Intrathecal chemotherapy, NM treatment
 - aseptic meningitis, 195
 - chemotherapeutic agents, 193–194
 - delayed leukoencephalopathy, 196
 - topoisomerase-II inhibitor, 195
 - Intravital multiphoton laser scanning microscopy (MPLSM), 81
- K**
- Karnofsky performance status (KPS), 5, 10, 113, 202, 212
- L**
- Leptomeningeal dissemination (LMD), 115, 120
 - Leptomeningeal metastasis. *See* Neoplastic meningitis (NM)
- M**
- Magnetic resonance imaging (MRI)
 - blood pool agents, 73
 - blooming artifact, 74
 - breast cancer cells, 74–75
 - cell tracking, 74
 - differential ADC and dynamic contrast-enhancement characteristics, 71, 73
 - diffusion weighted imaging, 74
 - image contrasts, 70–71

- Magnetic resonance imaging (MRI) (*cont.*)
 superparamagnetic iron oxide nanoparticles, 72
 volume measurements, enhancing vs. nonenhancing metastasis, 71–72
- Magnetic resonance spectroscopy (MRS), 75–76
- Medical treatment, brain metastasis
 antiepileptic drugs, 136
 definitive therapy, 135
 dexamethasone, 136
 symptomatic therapy, 135
- Melanoma
 BRAF, brain metastasis, 97–98
 cytotoxic T lymphocyte antigen 4 immunomodulators, 98
- Metastatic tumor cell interactions
 with astrocyte, 50–51
 with microglia, 48–49
 with neuron, 47–48
- Microenvironment. *See* Brain microenvironment
- Microglia, 45
- Mouse models
 activated astrocytes, 46
 breast cancer brain metastasis, 76
 vs. human samples, 17–18, 20
 PEDF, 34
 $\alpha_v\beta_3$ integrin, 27
 VEGF, 26, 90
- MRI. *See* Magnetic resonance imaging (MRI)
- Multi-agent chemotherapy, 143
- Multimodality imaging, 82–83
- N**
- Neoplastic meningitis (NM)
 clinical presentation, 188–189
 diagnosis of
 CSF examination, 189–190
 MRI, 190–191
 epidemiology, 188
 palliative care, 197–198
 pathogenesis, 188
 prognosis, 191
 treatment, 191–192
 intrathecal chemotherapy, 193–196
 radiation therapy, 193
 surgery, 192–193
 systemic chemotherapy, 196–197
- Neuroinflammatory response, 17–19
- Neurons, 44
- Nomograms, 8
- Non-small cell lung cancer (NSCLC)
- EGFR
 dose escalation strategies, 97
 gefitinib and erlotinib, 95, 97
 phase II trials, 95–96
- HER2
 afatinib, 95
 lapatinib, 94–95
 MDA-MB-231, 93
 trastuzumab, 94
- O**
- Oligodendrocytes, 46
- P**
- Pericytes, 46
- Pigment epithelium-derived factor (PEDF), 33–34
- Positron emission tomography (PET)
 hypoxia, 77–78
 natural biological molecules, 76
 proliferation rate and DNA replication, 77
 upregulated cell surface receptors, 78
- Pre-radiation chemotherapy, 144
- Primary brain tumors
 antiangiogenic agents, 91
 BTB, 58
 MRI, 74, 76
 QOL, 208, 211
 radiosensitizers, 159
- Prophylactic cranial irradiation (PCI)
 biomarkers, 172
 definition, 170
 neurocognitive function and quality of life assessments, 171
 risk-benefit ratio, 171
- Q**
- Quality of life (QOL)
 activities of daily living, 209
 assessment instruments
 functional impairment, 206
 Karnofsky performance status, 202
 SQLI, 206
 subjective and objective measures, 202–205
 and depression, 210–211
 effect of psychotherapy, 209
 intervention, 211–212
 physical functioning scores, 210
 predictors of, 207
 and survival prediction, 212

and treatment
 activities of daily living, 207
 factors, 208
 motexafin gadolinium, 209
 neurocognitive functioning, 208

R

Radiation therapy

apoptosis, 154
 BBB, 161–162
 cost-effectiveness, 179
 fractionation vs. single dose
 biologically equivalent dose, 156
 cellular radiosensitivity, 157
 cognitive effects, 156
 damage, 157
 factors, 154
 oxygen-mimetic agents, 155
 prescribed dose, 154
 radiation limits, 155–156
 toxicities, 155
 future aspects, 179–180
 immunomodulator, 160–161
 ionizing radiation, 153
 neoplastic meningitis treatment, 193
 sensitizers
 agents, 158–159
 in clinical trials, 160
 differential effect, 158
 HDAC inhibitors, 159
 intertumor and intratumor
 heterogeneity, 159
 spinal metastasis treatment,
 177–179
 stereotactic radiation
 dose conformity, 174
 fiducial markers, 173
 Hopkins Verbal Learning
 Test-Revised, 176
 hypofractionation, 177
 institutional constrains, 175
 linear accelerators, 172
 modality, 173
 MRI, 174
 single fraction treatment, 176
 surgery benefit, 172
 techniques
 attenuation process, 163
 Gamma Knife units, 166
 helical tomotherapy unit, 166–167
 immobilization devices for head,
 163–164
 linear accelerators, 164, 166

opposed-lateral field arrangements,
 163, 165
 single and multiple brain metastase, 162
 WBRT, 167–172

Radiation therapy oncology group (RTOG),
 94, 114, 137, 167

Recursive partitioning analysis (RPA),
 114, 169, 202

S

Signal transducer and activator of transcription
 3 (STAT3), 31

Single agent chemotherapy
 for breast cancer, 139–140

EGFR inhibitors, 142

fotemustine, 141

lapatinib, 142–143

NSCLC treated with erlotinib, 140, 142

temozolomide, 139, 141

topotecan, 139, 141–142

Single photon emission computed tomography
 (SPECT), 78

Small cell lung cancer (SCLC)

chemotherapy (*see* Chemotherapy)

lung cancer, 4–6

Spinal metastasis, radiation therapy, 177–179

Spitzer quality of life index (SQLI), 206

Spontaneous metastasis model, 17

Stereotactic radiosurgery (SRS)

dose conformity, 174

fiducial markers, 173

Hopkins Verbal Learning Test-Revised, 176

hypofractionation, 177

institutional constrains, 175

linear accelerators, 172

modality, 173

MRI, 174

single fraction treatment, 176

surgery benefit, 172

ST6GALNAC5, 32–33

Surgery, brain metastasis

adjuncts

 direct cortical stimulation, 125

 phase reversal techniques, 123–124

 stereotaxis, 122–123

 ultrasound, 121–122

approaches, 120–121

complications, 126

history, 110–111

mortality, 126

multiple brain metastases, 117

post-operative management, 126

principles and goals, 119–120

- Surgery, brain metastasis (*cont.*)
 recurrent metastases, 118
 role of
 histological diagnosis, 111
 lesions, 112–113
 surgical resection, 112
 single brain metastases, 116
 survival, 126
 treatment
 degree of systemic disease control, 115
 graded prognostic assessment, 114
 patient selection, 113
 preoperative neurological status, 115
 primary tumor characteristics, 116
 recursive partitioning analysis, 114
 tumor size, 119
 WBRT after resection, 125–126
- Systemic chemotherapy. *See* Treatment of, brain metastasis
- T**
- Transcription factors, brain metastasis
 caveolin-1, 32
 Notch signaling, 28–29
 receptor tyrosine kinase-like orphan receptors, 30
 signal transducer and activator of transcription 3, 31
 T-cell factors, 30
 types, 28
 upstream receptor, 32
 Wnt/ β -catenin, 30
- Transforming growth factor β (TGF β), 35–36
- Treatment of, brain metastasis
 chemokine receptor and ligand, 135
 chemotherapy
 BBB, 137–138
 carmustine wafer implants, 140
 epidermal growth factor receptor inhibitors, 140
 issues, 136–137
 multi-agent, 143
 outcome measures, 137
 parenchymal brain drug delivery, 137–138
 pre-radiation, 144
 single agent (*see* Single agent chemotherapy)
 temozolomide, 139
 topotecan, 139
 colonization, 134
 medical
 antiepileptic drugs, 136
 definitive therapy, 135
 dexamethasone, 136
 symptomatic therapy, 135
 neoplastic meningitis treatment, 196–197
 WBRT with temozolomide, 145
- V**
- Vascular endothelial growth factor (VEGF), 25–27, 89–92
- Vascular permeability, brain metastasis
 BBB, 55–57
 BTB, 57–60
 drug accumulation and effect, 63
 kinetic analysis and drug uptake, 64–65
- W**
- WBRT. *See* Whole brain radiotherapy (WBRT)
- Whole-body optical imaging
 bioluminescence imaging, 79–80
 fluorescent imaging, 79
 sensitivity and high throughput, 78
 stress effect, 80
 tyrosine kinase inhibitor, 79
- Whole brain radiotherapy (WBRT)
 adriamycin, 168
 dementia, 168
 dose limiting toxicity, 170
 prophylactic cranial irradiation, 170–172
 recursive partitioning analysis, 169
 side effects, 168
 symptomatic control, 167
 WNT pathway, brain metastasis, 98–99